Fabry international prognostic index: A predictive severity score for Anderson-Fabry disease

Journal of Medical Genetics

Volumn 49, Issue 3, 2012, Pages 212-220

  Hughes, Derralynn A ^a   Malmenäs, Mia ^b   Deegan, Patrick B ^c   Elliott, Perry M ^d   Ginsberg, Lionel ^a   Hajioff, Daniel ^e   Ioannidis, Alex S ^f   Orteu, Catherine H ^a   Ramaswami, Uma ^c   West, Michael ^g   Pastores, Gregory M ^h   Jenkinson, Crispin ⁱ  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Global Outcome Surveys   (Sweden)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^f SYDNEY EYE HOSPITAL   (Australia)

^g DALHOUSIE UNIVERSITY   (Canada)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDERSON FABRY DISEASE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; EVENT FREE SURVIVAL; FABRY DISEASE; FABRY INTERNATIONAL PROGNOSTIC INDEX; HEART DISEASE; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL;

ADULT; DNA MUTATIONAL ANALYSIS; FABRY DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84860312738     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2011-100407     Document Type: Article

References (21)

1. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science 1970;167:1268-9.
2. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G; FOS investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52.
3. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
4. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24(Suppl 2):13-14.
5. Deegan PB, Baehner AF, Barba romero MA, Hughes DA, Kampmann C, Beck M; European FOS investigators. Natural history of fabry disease in females in the fabry outcome survey. J Med Genet 2006;43:347-52.
6. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Brühl K, Gal A, Bunge S, Beck M. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-24.
7. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
8. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40.
9. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
10. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-22.
11. West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132-9.
12. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-48.
13. Beck M. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl 2006;95:43-6.
14. Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for Fabry disease. Mol Genet Metab 2010;99:283-90.
15. Hughes DA. The use of scoring systems in patients with haematological malignancy. Acta Paediatr Suppl 2006;95:47-51.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
18. Moore DF, Ries M, Forget EL, Schiffmann R. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. Pharmacoeconomics 2007;25:201-8.
19. Barba-Romero MA, Deegan P, Giugliani R, Hughes D. Does geographical location influence the phenotype of Fabry disease in women in Europe? Clin Genet 2010;77:131-40.
20. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT. Patients with fabry disease on dialysis in the United States. Kidney Int 2002;61:249-55.
21. Mehta A, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Lid-ove O. Therapeutic goals in the treatment of Fabry disease. Genet Med 2010;12:713-20.